Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol
1 Department of Family Medicine Research, Faculty of Medicine, University of Manitoba, P228-770, Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada
2 Departments of Family Medicine (Research Director) and Community Health Sciences, Faculty of Medicine, University of Manitoba, P228-770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada
3 Professor, Department of Community Health Sciences, Manitoba Centre for Health Policy (Director), Faculty of Medicine, University of Manitoba, Manitoba, Canada
4 Director, Primary Care Oncology Program, CancerCare Manitoba; Associate Professor, Departments of Family Medicine and Internal Medicine, University of Manitoba; Chair, Canadian Association of General Practitioners in Oncology, Manitoba, Canada
5 Population Oncology, CancerCare Manitoba, Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Manitoba, Canada
6 Associate Professor, Faculty of Nursing, University of Manitoba, Manitoba, Canada
7 Professor, Faculty of Nursing, University of Manitoba; Research Associate, Manitoba Palliative Care, Research Unit, CancerCare Manitoba, Manitoba, Canada
Citation and License
BMC Cancer 2012, 12:182 doi:10.1186/1471-2407-12-182Published: 17 May 2012
Fecal occult blood test screening in Canada is sub-optimal. Family physicians play a central role in screening and are limited by the time constraints of clinical practice. Patients face multiple barriers that further reduce completion rates. Tools that support family physicians in providing their patients with colorectal cancer information and that support uptake may prove useful. The primary objective of the study is to evaluate the efficacy of a patient decision aid (nurse-managed telephone support line and/or colorectal cancer screening website) distributed by community-based family physicians, in improving colorectal cancer screening rates. Secondary objectives include evaluation of (dis)incentives to patient FOBT uptake and internet use among 50 to 74 year old males and females for health-related questions. Challenges faced by family physicians in engaging in collaborative partnerships with primary healthcare researchers will be documented.
A pragmatic, two-arm, randomized cluster controlled trial conducted in 22 community-based family practice clinics (36 clusters) with 76 fee-for-service family physicians in Winnipeg, Manitoba, Canada. Each physician will enroll 30 patients attending their periodic health examination and at average risk for colorectal cancer. All physicians will follow their standard clinical practice for screening. Intervention group physicians will provide a fridge magnet to each patient that contains information facilitating access to the study-specific colorectal cancer screening decision aids (telephone help-line and website). The primary endpoint is patient fecal occult blood test completion rate after four months (intention to treat model). Multi-level analysis will include clinic, physician and patient level variables. Patient Personal Health Identification Numbers will be collected from those providing consent to facilitate analysis of repeat screening behavior. Secondary outcome data will be obtained through the Clinic Characterization Form, Patient Tracking Form, In-Clinic Patient Survey, Post-Study Follow-Up Patient Survey, and Family Physician Survey. Study protocol approved by The University of Manitoba Health Research Ethics Board.
The study intervention has the potential to increase patient fecal occult blood test uptake, decrease colorectal cancer mortality and morbidity, and improve the health of Manitobans. If utilization of the website and/or telephone support line result in clinically significant increases in colorectal cancer screening uptake, changes in screening at the policy- and system-level may be warranted.
Clinical trials.gov identifier NCT01026753